Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vomiting07.01.07.0030.017427%
Tubulointerstitial nephritis20.05.02.0020.001364%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.000818%Not Available
Fibromyalgia15.05.02.002--Not Available
Musculoskeletal disorder15.03.05.0250.000667%Not Available
Rheumatoid nodule15.01.03.002; 23.07.04.004; 10.04.06.002--Not Available
Joint range of motion decreased15.01.02.0060.001697%
Poor venous access24.03.02.017--Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.000455%Not Available
Deafness unilateral04.02.01.011--Not Available
Hypoacusis04.02.01.006--
Pityriasis lichenoides et varioliformis acuta23.03.08.002; 10.04.02.010--Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Weight fluctuation14.03.02.002--Not Available
Emotional distress19.04.02.008--Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.012--Not Available
Intervertebral disc protrusion15.10.01.0040.000303%Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.0030.001515%Not Available
Conjunctival hyperaemia06.04.01.0040.000303%Not Available
Bone erosion15.02.04.0190.000667%Not Available
Infantile genetic agranulocytosis01.02.03.012; 03.15.02.002--Not Available
Lymphatic disorder01.09.01.003--Not Available
Drug tolerance decreased08.06.01.024--Not Available
Musculoskeletal stiffness15.03.05.0270.007910%Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin swelling23.03.03.039--Not Available
Injection site swelling08.02.03.017; 12.07.03.0180.001182%Not Available
Secretion discharge08.01.03.019--Not Available
Type IV hypersensitivity reaction10.01.03.0220.000303%Not Available
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene